#### **DECLARATION**

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: NEUROPROTECTIVE EFFECTS OF ATF6, the specification of which is attached and was filed on July 30, 2004, as PCT International Application No. PCT/US2004/024571.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
			☐ YES ☐ NO
			YES NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing
60/491,565	August 1, 2003

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor	Inventor's Signature	Date
Byron ZHAO	Byron B. Thero	3/31/06
Residence		Citizenship
Palo Alto, California		USA
Post Office Address		8AK
380 Vallejo Drive, #131, Millbrae, CA 940	30	

Full Name of Second Inventor	Inventor's Signature	Date
Mei YU		3/31/06
Residence		Citizenship
San Francisco, California		USA
Post Office Address		
2418 23 <sup>rd</sup> Avenue, San Francisco	, CA 94116	

PAP

# 10/575457 AP9 Rec'd PCT/PTO 12 ARR 2006

Customer No. 22,852 Attorney Docket No. 8576.0004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Byron ZHAO et al.	) Group Art Unit: Unassigned
Application No.: (filed herewith)	) Examiner: Unassigned
Filed: July 30, 2004 (as PCT/US2004/024571)	) Confirmation No.: Unassigned )
For: NEUROPROTECTIVE EFFECTS OF ATF6	) ) )
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	

Sir:

## SUBMISSION UNDER 37 C.F.R. § 3.73(b)

Assignee, Elan Pharmaceuticals, Inc., duly organized under the laws of Delaware and having its principal place of business at 800 Gateway Boulevard, South San Francisco, California, 94080, represents that it is the assignee of the entire right, title and interest in and to the above-identified application NEUROPROTECTIVE EFFECTS OF ATF6, the specification of which is attached and was filed on July 30, 2004, as PCT International Application No. PCT/US2004/024571, in the names of Byron ZHAO and Mei YU, as indicated by the true and correct copy of the original assignment attached hereto, which is being concurrently submitted for recordation.

The undersigned (whose title is supplied below) is authorized to act on behalf of assignee.

Respectfully submitted,

Name:

: Carl W. Battle

Title:

Senior Vice President,

Intellectual Property Counsel

Assignee:

Elan Pharmaceuticals, Inc.

Dated: April 6, 2006

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of:	)
Byron ZHAO et al.	) Group Art Unit: Unassigned
Application No.: (filed herewith)	) Examiner: Unassigned
Filed: July 30, 2004 (as PCT/US2004/024571)	) Confirmation No.: Unassigned )
For: NEUROPROTECTIVE EFFECTS OF ATF6	) ) )
Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	

**POWER OF ATTORNEY BY ASSIGNEE** 

Sir:

Assignee, Elan Pharmaceuticals, Inc., duly organized under the laws of Delaware and having its principal place of business at 800 Gateway Boulevard, South San Francisco, California, 94080, represents that it is the assignee of the entire right, title and interest in and to the above-identified application NEUROPROTECTIVE EFFECTS OF ATF6, the specification of which is attached and was filed on July 30, 2004, as PCT International Application No. PCT/US2004/024571, in the names of Byron ZHAO and Mei YU, as indicated by the Statement Under 37 C.F.R. § 3.73(b) filed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of assignee Elan Pharmaceuticals, Inc.

I hereby appoint the following attorney and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected

therewith. FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., CUSTOMER NUMBER 22,852.

Respectfully submitted,

Name:

Carl W. Battle

Title:

Senior Vice President,

Intellectual Property Counsel

Assignee:

Elan Pharmaceuticals, Inc.

Dated: April 6, 2006